{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T01:23:14Z","timestamp":1785201794547,"version":"3.55.0"},"reference-count":26,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2017,11,2]]},"DOI":"10.1080\/10428194.2017.1306642","type":"journal-article","created":{"date-parts":[[2017,7,25]],"date-time":"2017-07-25T08:02:23Z","timestamp":1500969743000},"page":"2548-2557","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":24,"title":["Pralatrexate: a comprehensive update on pharmacology, clinical activity and strategies to optimize use"],"prefix":"10.1080","volume":"58","author":[{"given":"Owen A.","family":"O\u2019Connor","sequence":"first","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Amengual","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Colbourn","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Changchun","family":"Deng","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Sawas","sequence":"additional","affiliation":[{"name":"Department of Medicine, College of Physicians and Surgeons, Center for Lymphoid Malignancies, Columbia University Medical Center, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2017,7,25]]},"reference":[{"key":"CIT0001","first-page":"551","volume":"69","author":"Schmid FA","year":"1985","journal-title":"Cancer Treat Rep"},{"key":"CIT0002","first-page":"127","author":"Sirotnak FM","year":"1987","journal-title":"NCI Monogr"},{"key":"CIT0003","first-page":"26","volume":"12","author":"Sirotnak FM","year":"1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1002\/1097-4652(200009)184:3<364::AID-JCP11>3.0.CO;2-N"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.17.11165"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.nutr.19.1.91"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-013-2231-9"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.8470"},{"key":"CIT0009","first-page":"3493","volume":"6","author":"Krug LM","year":"2000","journal-title":"Clin Cancer Res"},{"key":"CIT0010","first-page":"2072","volume":"9","author":"Krug LM","year":"2003","journal-title":"Clin Cancer Res"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2009.80"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.9024"},{"key":"CIT0013","doi-asserted-by":"crossref","unstructured":"Shustov A, Pro B, Gisselbrecht C. Pralatrexate is effective as second-line treatment following cyclophosphamide\/doxorubicin\/vincristine\/prednisone (CHOP) failure in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). ASH Annual Meeting Abstr. 2010.","DOI":"10.1182\/blood.V116.21.4882.4882"},{"key":"CIT0014","doi-asserted-by":"crossref","unstructured":"Goy A, Pro B, Savage K, et\u00a0al. Pralatrexate is effective in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) with prior ifosfamide, carboplatin, and etoposide (ICE)-based regimens. ASH Annual Meeting Abstracts; 2010.","DOI":"10.1182\/blood.V116.21.1753.1753"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-11-390211"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1172\/JCI106181"},{"key":"CIT0017","doi-asserted-by":"crossref","unstructured":"Haddad PA. Efficacy of short oral leucovorin rescue (SOLR) in managing recurrent pralatrexate (Folotyn) induced mucositis (RPIM) despite dose reduction. Blood (ASH Annual Meeting Abstracts); 2011.","DOI":"10.1182\/blood.V118.21.4745.4745"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.779688"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-014-2580-z"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0331"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-0671"},{"key":"CIT0022","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2249"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-0033"},{"key":"CIT0024","first-page":"521","volume":"33","author":"Hoovis ML","year":"1973","journal-title":"Cancer Res"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.1172\/JCI109525"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2603"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2017.1306642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T08:57:17Z","timestamp":1602579437000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2017.1306642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,25]]},"references-count":26,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2017,5,9]]},"published-print":{"date-parts":[[2017,11,2]]}},"alternative-id":["10.1080\/10428194.2017.1306642"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2017.1306642","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"}]}}